46 results about "Tumor reduction" patented technology

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.

Disclosed herein are compositions and methods for treating cancer, specifically extensive-stage small-cell lung cancer (ES-SCLC), through the administration of a combination therapy. In some embodiments, the method comprises administering plinabulin, one or more immune checkpoint inhibitors, including but not limited to pembrolizumab, and a regimen of etoposide with a platinum-based agent (EP). The disclosed methods enhance tumor reduction, prolong progression-free survival, and improve overall treatment efficacy compared to traditional therapies.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition containing carboxamide triazole or pharmaceutically acceptable salts thereof and application of the pharmaceutical composition in preparation of medicines for preventing or treating fibrosis-related diseases. Specifically, the invention discovers that the carboxylamine triazole orotate (CTO) can directly inhibit fibroblast collagen generation and cross-linking maturation, so that the fibrosis degree is reduced; when the polypeptide is combined with a PD-1 antibody, collagen deposition in tumor tissues can be reduced by inducing normalization of a tumor matrix in a synergistic manner, the tumor permeation concentration of chemotherapeutic drugs is remarkably enhanced, and the anti-tumor curative effect is improved. The invention can be applied to the treatment of various matrix dense solid tumors including pancreatic cancer, breast cancer, colorectal cancer and lung adenocarcinoma, and is expanded for intervention of fibrosis-related diseases, thereby providing a new treatment strategy for improving the efficacy of chemotherapeutic drugs and improving immunotherapy response through targeted matrix remodeling.

The invention relates to the field of biological medicines, in particular to a PD-L1 targeting polypeptide and application thereof. The present invention provides a PD-L1 targeting polypeptide, which is characterized in that the polypeptide comprises a first fragment and a second fragment, the first fragment is used for binding with PD-L1, the second fragment is used for mediating degradation of PD-L1 in lysosome, and the first fragment comprises an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The polypeptide provided by the invention can promote the degradation of PD-L1 protein through lysosome, reduce the content of PD-L1 expressed by tumor cells and / or exosomes, fundamentally avoid and reduce the interaction between PD-L1 and PD-1, and have better inhibition effect and treatment effect.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

A method for treating head and neck tumors is provided, specifically relating to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for treating head and neck tumors, wherein the compound of formula (I) produces good efficacy in reducing tumor growth or even eliminating tumors.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The invention discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors, belongs to the technical field of anti-tumor traditional Chinese medicines, and discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-25 parts of ginseng, 15-18 parts of selfheal, 12-18 parts of seaweed, 12-19 parts of astragalus membranaceus, 10-16 parts of angelica sinensis, 18-30 parts of oldenlandia diffusa, 10-15 parts of fleece-flower root, 10-14 parts of poria cocos, 10-16 parts of thunberg fritillary bulb, 8-14 parts of pseudobulbus cremastrae seu pleiones and 8-17 parts of curcuma zedoary. Through the specific pharmacological action, growth and proliferation of thyroid tumor cells are inhibited, the development speed of tumors can be slowed down, the malignancy degree of the tumors can be reduced, apoptosis of the thyroid tumor cells can be induced, and the number of the tumor cells can be effectively reduced by inducing apoptosis of the tumor cells, so that the anti-tumor purpose is achieved.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of ethyl acetate extract of turmeric in the preparation of drugs for treating colorectal cancer. The preparation method of the extract is as follows: turmeric slices are soaked overnight in 15 times their weight of a 70% (v / v) ethanol solution, refluxed at 85°C three times, 2 hours each time. The extracts are combined and concentrated until no alcohol odor remains. The extract is then dried to constant weight to obtain the total extract. The total extract is reconstituted with water and extracted three times with ethyl acetate at an equal volume ratio. The extracts are combined and dried to constant weight to obtain the final product. Experimental results show that this extract is particularly effective in improving disease activity index, restoring colon length, reducing tumor number, and alleviating histopathological damage, and has no significant toxicity to major organs. This extract can be formulated into oral or injectable preparations, providing a new natural drug candidate for the treatment of colorectal cancer.

The application discloses a kind of dual targeting / drug-loaded reduction-sensitive nano-carrier, and the micelle is formed by the micelle of block polymer by solvent evaporation method, and the multi-block polymer is Tel-PEG-ss-PCL, the hydrophilic end of which is PEG with targeting group Tel, and the hydrophobic end is PCL, which is a core-shell structure, the core is the hydrophobic end PCL, and the shell is the hydrophilic block with targeting group Tel.The nano-carrier selects the polymer micelle with hydrophilic end polyethylene glycol and hydrophobic end polycaprolactone as drug carrier to improve the problem of poor water solubility of drug;Tel, an angiotensin II type receptor (AT1R) ligand, is used to simultaneously target CAFs and tumor cells overexpressing AT1R, kill tumor cells and CAFs, and double drug loading to overcome drug resistance;Meanwhile, disulfide bond is used to respond to high concentration glutathione (GSH) in tumor cells to achieve precise control release of drug in cells.The nano-carrier realizes the treatment effect of solubilization of poorly soluble drug, tumor and CAFs dual targeting and reversal of drug resistance.

The invention relates to a thermo-sensitive hydrogel drug sustained-release stent for jointly loading a hypotensive drug and a chemical / immunotherapy drug, which is prepared from a thermo-sensitive material and loads three drug components, namely losartan, oxaliplatin and an immune checkpoint inhibitor. The temperature-sensitive hydrogel can form gel in situ under the triggering of body temperature, and meanwhile, the acting time of the medicine on a target part is prolonged. The antihypertensive drug losartan potassium can reduce tumor interstitial substances, reduce tumor solid stress, relieve vascular compression in tumors and improve tumor hypoxia. Meanwhile, the chemotherapeutic drug oxaliplatin can induce tumor immunogenic cell death, and the tumor immunosuppressive microenvironment is effectively relieved. The immune checkpoint inhibitor can be used for accurately blocking the combination of the PD-L1 and the PD-1 and activating the T cell mediated anti-tumor immune response. According to the present invention, the potent anti-tumor immune response can be triggered, the excellent tumor inhibition effect can be achieved, the strong far-end effect can be even induced, and the growth of the far-end tumor can be effectively inhibited.

Described herein is a new mitochondrial peptide. This small peptide is capable of modulating cancer, through a variety of mechanisms including autophagy / apoptosis, reduction of tumor cell viability, inducing inflammatory response in senescent cells and conversion of macrophage cell type. Administration of the peptide, its analogs and derivatives thereof, are likely to be effective treatments for cancer therapy, including generation of synthetic analogs that further enhance or abrogate activity relative to the peptide.

The invention provides a traditional Chinese medicine preparation for early nasopharynx cancer, and belongs to the technical field of traditional Chinese medicine preparation. According to the traditional Chinese medicine preparation, American ginseng and prepared rehmannia root are used as monarch drugs, Chinese yam, rhizoma polygonati, adenophora tetraphylla, oviductus ranae and white hyacinth beans are used as ministers, lucid ganoderma, radix puerariae, radix angelicae, horsetail and amomum kravanh are used as assistants, Chinese dates are used as guides, and all the drugs are combined to achieve the effects of supporting healthy energy, reinforcing qi, nourishing yin, invigorating the spleen, tonifying the kidney, resolving dampness and dredging orifices. In-vitro experiment results show that the traditional Chinese medicine preparation has obvious proliferation and migration inhibition effects and apoptosis promotion effects on nasopharyngeal carcinoma cells. An in-vivo experiment result shows that the traditional Chinese medicine preparation can improve the adverse reaction of weight loss of a body caused by a traditional chemotherapeutic drug, can effectively reduce the tumor growth speed of a tumor-bearing mouse, remarkably reduces the tumor volume and mass, and has a remarkable inhibition effect on tumor growth. In addition, the traditional Chinese medicine preparation is combined with cis-platinum for use, so that the inhibition effect on tumor growth can be effectively enhanced.

The invention discloses application of dendrobium officinale polysaccharide in preparation of a PGC-1alpha signal channel inhibitor, and research shows that dendrobium officinale can regulate and control metabolic gene expression of macrophages in a tumor microenvironment, promote polarization of macrophages M1 and effectively inhibit occurrence and development of tumors; meanwhile, the dendrobium candidum polysaccharide can also promote glycolysis metabolism of tumor-related macrophages, remarkably promote expression of macrophage glycolysis-related genes, inhibit expression of oxidative phosphorylation genes and PGC-1alpha genes, effectively reduce the volume and size of tumors, inhibit PGC-1alpha signal channels in the macrophages and inhibit the growth of tumor cells. In addition, the dendrobium officinale polysaccharide can be used as a PGC-1alpha signal channel inhibitor for preparing antitumor drugs, and a new way is provided for improving the metabolic state in a tumor microenvironment and tumor immunotherapy.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ovarian cancer, a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: Astragalus membranaceus (Fisch.) Bunge, Ramulus Cinnamomi, Poria cocos (Schw.) Wolf, Semen Persicae, Gynostemma pentaphyllum (Thunb.) Makino, Radix Moutan, Magnolia officinalis Rehd. et Wils., and Hirudo nipponia Whitfield. The traditional Chinese medicine composition has the effects of benefiting qi and activating blood, removing blood stasis and dredging collaterals. Therefore, the traditional Chinese medicine composition is suitable for patients after surgery or radiotherapy and chemotherapy for ovarian cancer, and is also suitable for patients who cannot tolerate surgery or radiotherapy due to poor physical condition. The traditional Chinese medicine composition has the effects of reducing tumor cell proliferation, regulating tumor immunity, reducing toxicity and increasing efficacy. In the maintenance treatment stage, the traditional Chinese medicine composition can enhance the immunity of patients, prolong the survival period of patients, and improve the life quality of patients.

The pharmaceutical composition comprises the following components in parts by weight: 24 to 30 parts of raw radix astragali, 18 to 24 parts of cooked ligustrum lucidum, 15 to 24 parts of semen cuscutae, 12 to 18 parts of fried rhizoma atractylodis macrocephalae, 12 to 18 parts of fried white peony root, 15 to 24 parts of fried cortex moutan, 15 to 24 parts of processed rhizoma pinelliae, 12 to 18 parts of radix scutellariae, 9 to 12 parts of fried fructus xanthii, 15 to 24 parts of radix rehmanniae recen and 24 to 30 parts of hedyotis diffusa. The traditional Chinese medicine is prepared from 24-30 parts of sculellaria barbata, 15-24 parts of wooden bun, 15-24 parts of selaginella tamariscina, 15-24 parts of geranium wilfordii and 6-9 parts of honey-fried licorice root. Compared with the prior art, the traditional Chinese medicine composition can effectively shorten the treatment time of thrombocytopenia caused by tumor treatment, and has better clinical application value.

The invention provides engineering probiotics EcN-Vh as well as a construction method and application thereof, and belongs to the technical field of biological medicines. According to the present invention, the engineering probiotic capable of expressing the BTApep-TAT is constructed through the bioengineering technology, the BTApep-TAT is expressed through the plasmid integration mode, the release of the peptide is achieved by using the arabinose-induced cracking system, and the engineering probiotic is used for the in-vivo sustainable production of the BTApep-TAT. The engineering probiotic EcN-Vh disclosed by the invention can continuously generate an inhibitory peptide BTApep-TAT of a targeted BORIS (Bovine Biosensor), and is used for treating the colorectal cancer. According to the probiotics, by inhibiting ADP-ribosylation and Wnt / beta-catenin signal channels of BORIS, the occurrence rate and progress of tumors are remarkably reduced, and a novel, safe and efficient probiotic delivery system is provided for treatment of colorectal cancer.

The present disclosure relates to methods of coupling antic-cancer agents and anti-cancer treatments to improve the efficacy of the overall treatment. The anti-cancer agent reduces stroma in the tumor microenvironment, in part by killing stroma producing cells such as TAFs and TAMs. Reduction of tumor stroma not only improves immune cell function, including immune cells administered in a second treatment, but also allows allowing other anti-cancer treatments to better access to tumor cells.

Among the various aspects of the present disclosure is the provision of an engineered yeast for delivery of immune checkpoint inhibitor (ICI) proteins to gastrointestinal tumors. The present teachings include methods for suppressing or reducing tumors through the administration of an engineered Sb that can deliver immune checkpoint inhibitors (ICIs) into the gastrointestinal tract. The present teachings also include a composition of a genetically engineered Sb consisting of Sb capable of expressing and secreting ICIs.

The invention discloses application of andrographolide and a pharmaceutical composition thereof in preparation of a medicine for preventing and / or treating lung cancer, particularly lung metastatic tumor, and belongs to the technical field of medicine. In-vivo and in-vitro experiments of a system prove that andrographolide can inhibit activation of a nuclear factor kappa B (NF-kappa B) signal channel by down-regulating expression of glycogen synthase kinase 3beta (GSK3beta), and particularly, phosphorylation and nuclear translocation processes of an NF-kappa B p65 subunit Ser536 site are inhibited. According to the effect, transcription and expression of downstream target gene chemotactic factors CCL2 and CXCL1 are effectively reduced, finally, infiltration of tumor-related macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in tumor tissue is remarkably reduced, aggregation of anti-tumor immune cells such as CD8 + T cells is promoted, an immunosuppressive microenvironment is reversed into an immune activation state, and the immunosuppressive activity of tumor cells is improved. And lung cancer metastasis is inhibited from the source. The invention provides a brand new candidate drug and a clear action mechanism for clinical prevention and treatment of lung cancer metastasis, and has a good development prospect.

The application discloses a CDDO quinoline derivative with a structure as shown in formula III, R is selected from R1 is selected from R2 is selected from n is selected from an integer from 2 to 5. Pharmacological experimental researches show that the CDDO quinoline derivative can reduce the content of HIF-1 alpha protein of tumor cells, can inhibit tumor cell proliferation under hypoxia, and the inhibition effect on the proliferation of various tumor cells is significantly better than that of CDDO and CDDO-Me. The application discloses application of the CDDO quinoline derivative in preparation of an anti-tumor drug.

While immune checkpoint inhibitors (ICIs) have demonstrated the ability to enhance the immune response against tumors, a significant number of patients do not exhibit a response to the ICIs currently available. The present disclosure provides alternative ICIs. It relates to SLAMF6-binding molecules such as antibodies or antigen-binding fragments thereof that reduce or inhibit cis SLAMF6-SLAMF6 interactions, which negatively regulate T cell activation, and their uses for enhancing T cell activation and / or for preventing T cell exhaustion and / or for increasing the proportion of T cells infiltrating tumors and / or for reducing tumor growth. This mechanism does not require expression of SLAMF6 on tumor cells.

The application relates to the biomedical technology field and discloses application of BAZ2B gene as a target point in inhibition of drug efflux of tumor cells. The application successfully proves for the first time that an inhibitor of the BAZ2B gene or a coded protein has an inhibiting effect on the efflux of nanometer materials such as Au, SiO2 and micelles in cells. The efflux of FB@SR micelle nanometer materials to tumor cells (such as melanoma cells) is reduced by inhibiting the BAZ2B gene, and the boron content in the cells is increased. The FB@SR is used as a new type of boron delivery agent, and compared with cells without BAZ2B gene silencing, the boron content in the cells is increased after the BAZ2B gene is silenced, the BNCT treatment window is prolonged, and better and higher-quality treatment effects are obtained.

The invention relates to the technical field of medical data processing, and provides a training method and device for an ovarian cancer tumor reduction preoperative prediction model, and the method mainly comprises the steps: obtaining sample data of an ovarian cancer patient and a corresponding evaluation label; extracting first sample data and second sample data from the sample data, and respectively determining a first risk value and a second risk value according to the first sample data and the second sample data; inputting the first sample data into a first network model to extract text data features, and inputting the second sample data into a second network model to extract image data features; determining a first data feature through the first risk value and the text data feature, and determining a second data feature through the second risk value and the image data feature; and training a neural network model according to the first data feature, the second data feature and the evaluation label to obtain a prediction model, and carrying out pre-operation evaluation and prediction on the ovarian cancer tumor reduction operation through the prediction model.

The application provides a pancreatic cancer deep penetration ferroptosis nano preparation and a preparation method and application thereof, the nano preparation comprises a drug-loaded core and a MOF shell, the drug-loaded core is formed by polymerization of a ferroptosis inducer Erastin and a polymer material, and the MOF is formed by coordination of iron ions and tannic acid. The preparation method is as follows: iron ions, the polymer material and Erastin are mixed to form an organic phase solution, the solution is slowly dropped into a tannic acid aqueous phase solution, and the nano preparation is obtained through ultrasonic and stirring. The nano preparation constructed in the application can regulate the re-polarization of tumor-associated macrophages, thereby reducing the activation and collagen deposition of tumor-associated fibroblasts to regulate the dense tumor stroma, achieving deep penetration of the nano preparation, after reaching the deep part of the tumor, the iron ions and Erastin synergistically act to destroy the redox balance of tumor cells, improve the ferroptosis effect of tumor cells, and realize ferroptosis treatment of pancreatic cancer cells.

The present application relates to the field of nanobiomaterials, in particular to a drug-loaded nanovaccine and a preparation method and application thereof, so as to improve tumor treatment effect and biological safety. The drug-loaded nanovaccine comprises MIL-100(Fe) and a manganese-doped mesoporous silica carrier, the MIL-100(Fe) is coated on the outer surface of the manganese-doped mesoporous silica carrier, and the manganese-doped mesoporous silica carrier is loaded with sorafenib. The MF@SOR nanovaccine of the present application has very high biological safety. Meanwhile, the carrier of the present application is wrapped with a layer of MIL-100(Fe), the coating is very uniform and stable, which can further improve the bioavailability of sorafenib, maximize the use of drugs and reduce the toxic and side effects of drugs. In addition, the MF@SOR nanovaccine can also induce the body to produce immune memory, inhibit the recurrence and metastasis of tumors, the recurrence and metastasis of tumors are significantly reduced, and the treatment effect of tumors is significantly improved.

The application discloses an animal bifidobacterium capable of relieving ulcerative colitis related colorectal cancer and an application thereof, and belongs to the technical field of microorganisms and the technical field of medicines. The application provides an animal bifidobacterium lactis (Bifidobacterium animalis subsp. lactis) CCFM1383 with a preservation number of GDMCC No: 64443. The animal bifidobacterium lactis CCFM1383 can effectively improve the symptoms of ulcerative colitis related colorectal cancer, specifically in relieving the weight loss of mice, improving the survival rate, prolonging the colon length, reducing the number of tumor nodules, reducing the spleen index, reducing the tumor tissue proliferation marker, promoting the apoptosis of tumor cells, regulating the content of inflammatory factors, improving the content of tight junction proteins, inhibiting the expression of cancer signal pathway genes, and improving the content of colon indole propionic acid.